Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Tabimorelin
Overview
Tabimorelin is an orally active synthetic ghrelin mimetic and selective GHS-R1a agonist developed to stimulate growth hormone release. Unlike peptide analogues, tabimorelin was designed as a small molecule with improved oral bioavailability and stability.
Mechanism of Action
The therapeutic rationale centered on treating frailty, functional decline in the elderly, and conditions associated with growth hormone deficiency.
Research Summary & Key Findings
Phase 2 clinical trials evaluated tabimorelin in elderly hip fracture patients and in sarcopenia, with results published in the Journal of Clinical Endocrinology and Metabolism in 2007 showing increases in growth hormone and IGF-1 levels. Development was discontinued before Phase 3 completion, and no regulatory approval was pursued. Evidence supported hormonal activity but did not establish clinical benefit in functional outcomes.
Clinical Status
Tabimorelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Tabimorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Tabimorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Tabimorelin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsNo lawful pathway today
Tabimorelin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.